Author: digi

The Role of Pharmacometrics in Dose Prediction for Phase 1

June 13, 2025

The Role of Pharmacometrics in Dose Prediction for Phase 1 How Pharmacometrics Drives First-in-Human Dose Selection and Optimization Introduction Choosing the right starting dose for a first-in-human (FIH) study is one of the most critical—and challenging—decisions in early clinical development. Pharmacometrics, the science of interpreting and describing pharmacology using mathematical models, plays an increasingly vital…

Phase 1 (Safety and Dosage)

Data Integrity and Traceability in Long-Duration Phase 3 Studies: Building Trust Through Robust Data Management

June 13, 2025

digi

Data Integrity and Traceability in Long-Duration Phase 3 Studies: Building Trust Through Robust Data Management How to Maintain Data Integrity and Traceability in Long-Term Phase 3 Clinical Trials Why Data Integrity Matters in Long-Duration Phase 3 Trials Phase 3 clinical trials, especially those involving chronic conditions or long-term treatment outcomes, can span several years. Over…

Phase 3 (Confirmation and Monitoring)

Evaluating Full-Service CROs for Therapeutic Area Expertise

June 13, 2025

digi

Evaluating Full-Service CROs for Therapeutic Area Expertise Evaluating Full-Service CROs Based on Therapeutic Expertise Choosing a full-service Contract Research Organization (CRO) for your clinical trial requires more than comparing cost or timelines. One of the most critical factors is the CRO’s therapeutic expertise—its knowledge, experience, and infrastructure to conduct studies in your specific disease area….

Contract Research Organizations (CROs), Full-Service CROs

Incorporating PROs and QoL Data in Phase 4 Clinical Trials

June 13, 2025

digi

Incorporating PROs and QoL Data in Phase 4 Clinical Trials How to Integrate Patient-Reported Outcomes and Quality of Life Measures in Phase 4 Studies Introduction Phase 4 clinical trials are increasingly focused on more than just safety and efficacy. Regulatory bodies, payers, and patients now seek a fuller picture of treatment impact. This includes the…

Phase 4 (Post-Marketing Surveillance)

Comparing Home-Based vs Site-Based Monitoring in Clinical Trials

June 13, 2025

digi

Comparing Home-Based vs Site-Based Monitoring in Clinical Trials Comparing Home-Based and Site-Based Monitoring in Clinical Trials With the evolution of Decentralized Clinical Trials (DCTs), sponsors are increasingly exploring home-based remote monitoring as an alternative or supplement to traditional site-based monitoring. Both models offer unique advantages and challenges in the context of trial oversight, compliance, and…

Decentralized Clinical Trials (DCTs), Remote Patient Monitoring

Tech Tools to Streamline Start-Up Processes in Clinical Trials

June 13, 2025

digi

Top Digital Tools to Accelerate Clinical Study Start-Up Clinical study start-up is a resource-intensive and highly regulated phase of the trial lifecycle. It involves multiple stakeholders, critical document collection, and coordination across geographies. Fortunately, modern technology offers a wide array of tools designed to streamline these processes. This tutorial explores the essential tech tools that…

Clinical Research Operations, Study Start-Up Activities

Evaluating Drug Efficacy Using Parallel Methodology – Clinical Trial Design and Protocol Development

June 13, 2025

digi

Evaluating Drug Efficacy Using Parallel Methodology – Clinical Trial Design and Protocol Development “Assessing Medication Effectiveness with Parallel Techniques” Introduction Drug efficacy evaluation is a crucial part of the drug development process. It ensures that drugs are effective for their intended use. One of the common methods used in this evaluation process is the parallel…

Clinical Trial Design and Protocol Development, Parallel Group Designs

Involving CROs in Site Feasibility Planning for Clinical Trials

June 13, 2025

digi

How to Involve CROs in Site Feasibility Planning for Clinical Trials Contract Research Organizations (CROs) play a pivotal role in modern clinical trials, particularly in site feasibility and selection. Involving CROs early in feasibility planning not only expands site outreach but also introduces process efficiencies, global expertise, and technology infrastructure. This guide outlines best practices…

Site Feasibility Assessments, Site Management and Monitoring

Engaging Underserved Populations in Clinical Trials

June 13, 2025

digi

Engaging Underserved Populations in Clinical Trials Effective Strategies for Engaging Underserved Populations in Clinical Trials Improving representation in clinical trials is not just a moral imperative—it’s a scientific necessity. Underserved populations, including racial and ethnic minorities, rural communities, economically disadvantaged individuals, and those with limited healthcare access, remain significantly underrepresented in clinical research. This lack…

Patient Recruitment and Retention, Recruitment Strategies

Revising Informed Consent for Protocol Amendments in Clinical Trials

June 13, 2025

digi

Revising Informed Consent for Protocol Amendments in Clinical Trials How to Revise Informed Consent Following Protocol Amendments in Clinical Trials In the lifecycle of a clinical trial, changes to the protocol are common—whether due to safety findings, scientific advancements, regulatory updates, or operational needs. When such amendments affect the rights, safety, or well-being of participants,…

Informed Consent and Ethics Committees, Informed Consent Process